Physicians' approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 9, 2006, Pages 1365-1372

  Murthy, S K ^a   Kauldher, S ^a   Targownik, L E ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; AWARENESS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG SAFETY; DRUG USE; FEMALE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; OSTEOARTHRITIS; PATIENT SAFETY; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STOMACH PROTECTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL COMPETENCE; CYCLOOXYGENASE 2 INHIBITORS; FAMILY PRACTICE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PROFESSIONAL PRACTICE; PROTON PUMPS; RISK FACTORS;

EID: 33645723469     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02873.x     Document Type: Article

References (31)

1. Gabriel SE Jaakkimainen L Bombardier C Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis Ann Intern Med 1991 115 787 96
2. Langman MJ Weil J Wainwright P et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs Lancet 1994 343 1075 8
3. Garcia Rodriguez LA Jick H Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs Lancet 1994 343 769 72
4. Wolfe MM Lichtenstein DR Singh G Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs N Engl J Med 1999 340 1888 99
5. Lanas A Perez-Aisa MA Feu F et al. Investigators of the Asociacion Espanola de Gastroenterologia (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use Am J Gastroenterol 2005 100 1685 93
6. Griffin MR Piper JM Daugherty JR et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons Ann Intern Med 1991 114 257 63
7. Piper JM Ray WA Daugherty JR et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs Ann Intern Med 1991 114 735 40
8. Shorr RI Ray WA Daugherty JR et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease Arch Intern Med 1993 153 1665 70
9. Singh G Ramey DR Triadafilopoulos G et al. GI score: a simple self-assessment instrument to quantify the risk of serious NSAID-related GI complications in RA and OA (abstract) Arthritis Rheum 1998 41 Suppl. S75
10. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines Arthritis Rheum 2000 43 1905 15
11. Lanza FL A guideline for the treatment and prevention of NSAID induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology Am J Gastroenterol 1998 93 2037 46
12. Hunt RH Barkun AN Baron D et al. Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents Can J Gastroenterol 2002 16 231 40
13. Silverstein FE Graham DY Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial Ann Intern Med 1995 123 241 9
14. Silverstein FE Faich G Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: a randomized controlled trial JAMA 2000 284 1247 55
15. Bombardier C Laine L Reicin A et al. Rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 2000 343 1520 8
16. Yeomans ND Tulassay Z Juhasz L et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine Versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group N Engl J Med 1998 338 719 26
17. Hawkey CJ Karrasch JA Szczepanski L et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group N Engl J Med 1998 338 727 34
18. Spiegel BM Targownik L Dulai GS et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis Ann Intern Med 2003 138 795 806
19. Maetzel A Krahn M Naglie G The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis Arthritis Rheum 2003 49 283 92
20. Spiegel BMR Chiou C Ofman JJ Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups Arthritis Rheum (Arthritis Care Res) 2005 53 185 97
21. Hartnell NR Flanagan PS MacKinnon NJ et al. Use of gastrointestinal preventive therapy among elderly persons receiving antiarthritic agents in Nova Scotia, Canada Am J Geriatr Pharmacother 2004 2 171 80
22. Persson M Carlberg B Tavelin B et al. Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy J Hypertens 2004 22 65 71
23. Bresalier RS Sandler RS Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N Engl J Med 2005 352 1092 102
24. Solomon SD McMurray JJV Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 2005 352 1071 80
25. Laheij RJ Sturkenboom MC Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid suppressive drugs JAMA 2004 292 1955 60
26. Abraham HS El-Serag HB Johnson ML National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs Gastroenterology 2005 129 1171 8
27. Sturkenboom MC Burke TA Dieleman JP et al. Underutilization of preventive strategies in patients receiving NSAIDs Rheumatology (Oxford) 2003 42 Suppl. 3 iii23 31
28. Smalley W Stein CM Arbogast PG et al. Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs Arthritis Rheum 2002 46 2195 200
29. Friedmann PD Brett AS Mayo-Smith MF Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease Ann Intern Med 1999 124 414 21
30. Ilnyckyj A Bernstein CN Sexual abuse in irritable bowel syndrome: to ask or not to ask, that is the question Can J Gastroenterol 2002 16 801 6
31. Seguin R Godwin M MacDonald S et al. E-mail or snail mail? Randomized controlled trial on which works better for surveys Can Fam Physician 2004 50 414 9